Unicycive Therapeutics, Inc. (Thu, May 02, 2024)

Sell candidate since Apr 12, 2024 Loss -8.20%



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

score: -1 -9

#13812/30045

Trend:	Sell
MV Long:	Sell
MV Short:	Buy
Pivot:	Buy
Volume:	Sell
MACD:	Buy

Tech commentaries:

The Unicycive Therapeutics, Inc. stock price fell by -1.32% on the last day (Thursday, 2nd May 2024) from \$1.14 to \$1.12. During the last trading day the stock fluctuated 6.36% from a day low at \$1.10 to a day high of \$1.17. The price has fallen in 6 of the last 10 days but is still up by 2.75% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -31 thousand shares and in total, 238 thousand shares were bought and sold for approximately \$266.97 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -11.65% during the next 3 months and, with a 90% probability hold a price between \$0.84 and \$1.43 at the end of this 3-month period.

A buy signal was issued from a pivot bottom point on Thursday, April 25, 2024, and so far it has risen 15.46%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Unicycive Therapeutics, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the long-term average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at \$1.28. On a fall, the stock will find some support from the short-term average at \$1.09. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Unicycive Therapeutics, Inc. finds support from accumulated volume at \$1.09 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at \$1.14, \$1.22 and \$1.38.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved \$0.0700 between high and low, or 6.36%. For the last week the stock has had daily average volatility of 12.47%.

Unicycive Therapeutics, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Risk: High

Evaluation: Sell Candidate